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Summary Background The wet-wrap treatment involves emollients or corticosteroid dilutions under occlusive
wet dressings, and has been reported to be highly effective in severe refractory atopic dermatitis
(AD).
Objectives To investigate the influence of different corticosteroid dilutions on the efficacy and
hypothalamic±pituitary±adrenal (HPA) axis suppression in children with severe refractory AD
having wet-wrap dressings.
Methods Eighteen children were treated with a 50% dilution of fluticasone propionate (FP) 0´05%
cream for 2 weeks. In another five children a side-to-side comparison was conducted with 10%,
25% and 50% dilutions of FP cream under wet wrap. A third group of eight children was treated
with 0% ( emollient), 5%, 10% or 25% dilutions of FP cream applied on the whole body under wet
wrap.
Results After 1 week, a major improvement averaging 74% was observed, without apparent
differences between 5%, 10% or 25% dilutions of FP cream under wet wrap, with less improvement
in the second week of treatment. The first and second group of children showed HPA axis
suppression in only three of 23 children using measurements of 09´00 h serum cortisol after
2 weeks. The third group of children showed HPA axis suppression, as indicated by 06´00 h serum
cortisol levels, which was related to the absolute amount of FP applied.
Conclusions This suggests that weaker corticosteroid dilutions had comparable high efficacy, but
lower risk of HPA axis suppression.
Key words: atopic dermatitis, hypothalamic±pituitary±adrenal axis, topical corticosteroids,
wet-wrap dressings
Severe atopic dermatitis (AD) remains difficult to treat.
Although guidelines provide a good framework for
managing AD,1,2 some patients do not improve with
conventional therapy and pose a major therapeutic
problem. Cyclosporin, the most extensively studied
treatment for refractory AD, has been reported to be
effective in children with severe AD.3±5 However, cyclo-
sporin may have potentially severe side-effects, and
should not be given for longer than 3 months. In
children, therapies such as ultraviolet (UV) A-1,6
psoralen 1 UVA,7 recombinant interferon-g8 and sys-
temic corticosteroids are generally not indicated. Thus,
there is still a need for an effective treatment in children
with severe AD.
In 1991, Goodyear et al. described a highly effective
method of treatment with dressings in children with
severe erythrodermic AD.9 Their method involved a
wet-wrap technique involving the use of open-weave
cotton tubular dressings (Tubifast) impregnated with
a 10% dilution of betamethasone valerate 0´01%
cream applied twice daily according to a standard
protocol.9±11 They observed that 09´00 h cortisol
levels at the time of the wet-wrap application were
suppressed after 2±5 days, but returned to normal
2 weeks post-therapy.
We have developed a modified protocol using
fluticasone propionate (FP) 0´05% cream-emollient
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dilutions (50% on the body and 10% on the face) once
daily under wet-wrap dressings.12 FP is a potent corti-
costeroid that seems to have an improved benefit/risk
ratio.13,14 In the first part of the present study, 18
children were treated according to this protocol and the
systemic side-effects were assessed by 09´00 h serum
cortisol. However, 09´00 h serum cortisol is not a
sensitive marker of the systemic bioactivity of topical
corticosteroids, and other investigators have used
weaker corticosteroid dilutions. Therefore, in the
second part of the study, different dilutions of cortico-
steroids were compared and systemic bioactivity was
measured by 06´00 h serum cortisol and timed
morning urinary cortisol excretion.
The application of corticosteroids under occlusion
has previously been associated with a high rate of side-
effects, but the widely used technique of wet wrap has
not been satisfactorily evaluated. The purpose of this
study was to investigate the efficacy and the safety of
once-daily wet-wrap dressings with different dilutions




Thirty-one children (15 boys and 16 girls) with AD
according to the criteria of Sampson15 and Williams
et al.16 aged 5 months to 13 years, were included.
Disease severity was `severe' in 29 of the children
according to an objective SCORAD . 40.17 The wet-
wrap protocol we used was described previously.12
Briefly, the patients were admitted to hospital and took
a bath for 5±10 min once daily, followed by application
of the diluted FP 0´05% cream on the whole body. On
top of this we applied first a wet and then a dry layer of
tubular bandage made of cotton (Tubifastw, Seton
Scholl, Oldham, U.K.). This bandage was rewetted every
2 h with water using a spray bottle.
The first group consisted of 18 children who were
treated with a 50% dilution of FP cream under
wet-wrap dressings for 2 weeks. The objective SCORAD
and 09´00 h serum cortisol were measured at the
beginning and after 2 weeks of treatment.
The second group of five children had symmetrically
localized AD and was treated with different dilutions
(10%, 25% and 50%) of FP cream on the left and the
right side of the body under wet-wrap dressings. After
1 week, the severity of AD was scored by objective
SCORAD on both sides, and treatment was continued
with a 10% dilution of FP cream. The levels of 09´00 h
serum cortisol were measured at the beginning and
after 2 weeks of treatment.
The third group consisted of eight children who were
treated with different dilutions of FP cream: two each
with 0% ( emollient), 5%, 10% and 25%, under wet-
wrap dressings. Objective SCORAD and 06´00 h serum
cortisol were measured daily during the first week, and
after 2 weeks of treatment. Treatment with topical
corticosteroids was stopped 3 days before the baseline
cortisol value was assessed, and the total amount of FP
cream that was applied was recorded.
Clinical scoring system
The severity of AD was scored using the objective
SCORAD,17,18 which includes the assessment of two
items in a standardized manner: (i) extent (applying the
rule of nines), and (ii) intensity (erythema, oedema/
papulation, oozing/crust, excoriation, lichenification
and dryness on a scale of 0±3). This scoring system
reflects the modified consensus of the European Task
Force on AD. Unlike the initial version called SCORAD
index,19 subjective symptoms are not included in the
scoring of AD in the objective SCORAD.17,18
Safety analysis
To determine the systemic load of the topical medica-
tion we assessed the hypothalamic±pituitary±adrenal
(HPA) axis suppression. In the first two groups of
18 and five children, respectively, 09´00 h serum
cortisol levels were measured at the beginning and
after 2 weeks of treatment. In the third group of eight
children, 06´00 h serum cortisol and urinary timed
morning cortisol/creatinine ratio were measured daily
during the first week of treatment. Local side-effects
were assessed visually.
Statistical analysis
Statistical analysis was performed with SPSS 7´5 using
Wilcoxon's signed rank test in the first group of
children to analyse the improvement of AD and the
change in 09´00 h serum cortisol levels. The exact
McNemar's test was used in the first group of children
to assess the improvement of AD as categorized into
mild, moderate and severe. Spearman's rank corre-
lation was used in the third group of children to test
relationships between improvement of AD, absolute
amount of FP in mg m22 body surface daily, mean
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06´00 h serum cortisol on treatment and mean
timed morning cortisol/creatinine ratio on treatment.
Statistical significance was defined as P , 0´05.
Results
In the first uncontrolled group of 18 children, a signi-
ficant decrease in the objective SCORAD (Wilcoxon's
test, P , 0´0001) after 2 weeks of treatment was
observed in 17 children (Fig. 1a). One child was lost
to follow-up after 4 days of treatment due to personal
reasons. The severity of AD classified into mild, moderate
and severe according to the objective SCORAD decreased
in all 17 children (Table 1). For the evaluation of safety
we assessed the levels of 09´00 h serum cortisol at the
beginning of the treatment and after 2 weeks (Fig. 1b).
There was no significant decrease in the levels of serum
cortisol after 2 weeks of treatment (Wilcoxon's test,
P  0´24). However, serum cortisol levels were tem-
porarily below the normal range (0´2±0´8 mmol L21)
in three of the 18 children after 2 weeks, indicating a
suppression of the HPA axis.
To investigate the efficacy of different dilutions of
FP cream under wet wrap, a side-to-side comparison
was performed in five children with different dilutions
(10%, 25% and 50%) of FP cream on the left and the
right side. After 1 week of treatment, the objective
SCORAD had decreased markedly in all five children,
with no difference between the left and the right side
in objective SCORAD or affected body surface (Table 2).
We cannot exclude that this lack of difference is due
to a systemic effect. However, HPA axis suppression
was not evident in any of the five children as
assessed by 09´00 h serum cortisol (mean ^ SD
serum cortisol day 0, 0´42 ^ 0´16 mmol L21; day
14, 0´45 ^ 0´17 mmol L21). Furthermore, we observed
substantial improvement in AD after 1 week, with only
minor additional improvement in the second week of
treatment.
In the third group, three different dilutions of FP
cream (5%, n  2; 10%, n  2; 25%, n  2) were
applied on the whole body in six children and emollient
only in two children, under wet wrap. After 1 week, the
two children using only emollient under wet wrap
showed minor improvement, whereas the six children
in whom 5%, 10% or 25% dilutions of FP cream were
applied under wet wrap showed a major improvement
in AD (Fig. 2). There was no major difference in
efficacy between 5%, 10% and 25% dilutions of FP
cream (Fig. 2). A dose±response relationship was seen
with the absolute amount of FP in mg m22 daily
adjusted for dilution (Spearman's correlation r  0´97,
P , 0´0005; Fig. 3). An 80% improvement was
achieved with FP 800 mg m22 daily (equivalent to
1´6 g FP 0´05% cream). Absolute amounts of FP
. 957 mg m22 daily did not increase efficacy (Fig. 3).
Children using FP # 800 mg m22 daily had no
suppression of the HPA axis. Again, we observed
Figure 1. Graphs showing symptom score and systemic load of wet-
wrap dressings using a 50% dilution of fluticasone propionate 0´05%
cream in 18 children. (a) Objective SCORAD before and after 2 weeks
of treatment; (b) 09´00 h serum cortisol levels before and after
2 weeks of treatment. The shaded area indicates hypothalamic±
pituitary±adrenal axis suppression.
Table 1. Numbers of children with mild, moderate and severe atopic





Mild AD 0 11
Moderate AD 2 6
Severe AD 16 0
There was one drop-out due to personal reasons. After 2 weeks of
treatment, AD improved substantially (exact McNemar's test,
P , 0´0001).
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substantial improvement after 1 week, with little
further improvement in the second week of treatment.
Adverse events, other than HPA axis suppression, in
the first group (n  18), were upper respiratory tract
infection (n  6), folliculitis (n  6), herpes simplex
infection (n  1), diarrhoea (n  1) and itching
(n  1). In the second group (n  5), we observed
upper respiratory tract infection (n  2), folliculitis
(n  2), abdominal pain (n  1) and itching (n  1).
In the third group (n  8), we observed folliculitis
(n  5), balanitis (n  1) and furunculosis (n  1). A
generalized folliculitis was observed in both of the
children treated with only emollient during the first
week.
For a detailed analysis of HPA axis suppression,
06´00 h serum cortisol levels and timed morning
urinary cortisol/creatinine ratio were measured daily
in the third group of eight children (Table 3). A
relationship was found between the daily absolute
amount of FP applied (mg m22 body surface daily) and
the mean of the daily measurements of 06´00 h serum
cortisol levels on treatment over a 7-day period
(Spearman's test r  2 0´73, P , 0´05, n  8). How-
ever, there was no relationship between the daily
absolute amount of FP applied and the mean of daily
measurements of timed morning urinary cortisol/
creatinine ratio on treatment over a 7-day period
(Spearman's test r  2 0´38, P  0´5, n  6).
Discussion
The results of the present study show a dramatic
improvement in AD irrespective of the dilution of FP
(5%, 10%, 25% and 50%) applied under wet wrap. This
is demonstrated both in a left-to-right side comparison
in five children and by application of different dilutions
in eight children. The improvement of AD was related
to the absolute amount of applied corticosteroid in
mg m22 body surface. However, absolute amounts of FP
Patient, treatment
Left
beginning ! after 1 week
Right
beginning ! after 1 week
A, 10% vs. 50% 44 (65%)a ! 9 (10%) 44 (65%) ! 9 (10%)
B, 25% vs. 50% 50 (55%) ! 16 (26%) 50 (55%) ! 16 (26%)
C, 10% vs. 25% 55 (50%) ! 13 (10%) 59 (30%) ! 13 (10%)
D, 10% vs. 25% 43 (60%) ! 14 (10%) 43 (66%) ! 14 (10%)
E, 10% vs. 50% 40 (35%) ! 12 (20%) 40 (35%) ! 12 (20%)
aThe values in the table indicate objective SCORAD and the affected body surface in percentage.
An objective SCORAD # 15 indicates mild AD, 15±40 indicates moderate AD and . 40 indicates
severe AD.
Table 2. Objective SCORAD and extent of
atopic dermatitis (AD) in five patients before
and after 1 week of wet wrap with different
dilutions of fluticasone propionate on the left
and the right side
Figure 3. Graph showing the relative improvement of atopic
dermatitis (AD) at 7 days against the absolute amount of fluticasone
propionate (FP) in mg m22 body surface daily in children treated with
different dilutions [two each with 0% ( emollient) 5%, 10% and
25%] of FP 0´05% cream.
Figure 2. Graph of the relative improvement of atopic dermatitis
(AD) in group 3 comprising eight children treated with different
dilutions [two each with 0% ( emollient), 5%, 10% and 25%] of
fluticasone propionate 0´05% cream. The improvement of AD was
measured by objective SCORAD. Lines represent the means of two
patients.
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. 800 mg m22 daily hardly increased efficacy. Taken
together, these results indicate that weaker dilutions of
FP cream under wet wrap may have efficacy similar to
that of stronger dilutions. The improvement in AD
occurred mainly during the first week of treatment.
During the second week of treatment minor additional
improvement was observed, indicating that 1 week of
treatment with wet wrap is sufficient.
Most of the side-effects during the first 2 weeks of
treatment were probably not related to the treatment.
Mild to moderate folliculitis, mainly on the legs, was
observed in a large proportion of the children and
appears to be related to the treatment. Interestingly,
both children treated with only emollient under wet
wrap had generalized but mild folliculitis after 4 days.
Thus, folliculitis under wet-wrap therapy may be
related to occlusion, but in some cases corticosteroids
under wet wraps may aggravate the condition.
HPA axis suppression was measured by morning
serum cortisol levels. In the first and the second group
of children, 09´00 h serum cortisol levels were below
the normal range (0´2±0´8 mmol L21) in three of 18
in the first group and none of five in the second
group of children. However, 09´00 h serum cortisol
has been reported to have large intra- and inter-
individual variability, which makes it a rather insensi-
tive screening method for the systemic bioactivity of
topical corticosteroids.20 Therefore, in the third group
of eight children, we determined daily 06´00 h serum
cortisol levels. The collection time is crucial as a three-
fold difference in the levels of serum cortisol between
08´00 h and 10´00 h has been documented.21
Additionally, urinary timed morning cortisol/
creatinine ratio was assessed, as this measure is
reported to have excellent sensitivity.22,23 Using
06´00 h serum cortisol levels we observed evidence of
HPA axis suppression related to the absolute amount of
applied corticosteroid. This suggests that decreasing the
amount of applied corticosteroid would improve the
systemic safety without affecting the efficacy.
FP is a corticosteroid combining potent local efficacy
with relatively limited suppression of the HPA
axis.13,14,24 This improved topical/systemic activity
ratio25 is of particular benefit in children, who have a
high ratio of body surface to body weight.26 In an
earlier report, Goodyear et al.9 reported that 09´00 h
cortisol levels were uniformly low in all of 30 children
after 2±5 days of wet-wrap treatment with dilutions of
betamethasone valerate 0´01% cream. The difference
may be explained partly by their use of twice daily
application and also due to the use of a different
corticosteroid. A recent review on the efficacy of once
daily vs. twice daily applications of corticosteroids
reported no evidence to support an advantage of
multiple daily applications.27
No data are yet available on the efficacy and safety of
long-term treatment with wet wrap. We are currently
investigating the wet wrap for the long-term treatment
of AD. Goodyear et al.9 reported that long-term treat-
ment with wet wraps in five patients at home was
unsuccessful because of time-consuming application,
decreasing effectiveness, infection and HPA axis sup-
pression. The mode of action of the wet-wrap method is
probably a combination of protection of the skin from
scratching, cooling of the skin (thereby reducing
itching and inflammation), and enhanced penetration
of emollients and corticosteroids. Therefore, it is import-
ant to establish protocols that are safe and to be aware
of the possibility of HPA axis suppression.
The present study is limited by the small sample size
and differing measures of HPA axis suppression, and
cannot claim to have proved FP under wet wraps to be
Table 3. Amount of fluticasone propionate
(FP) in mg m22 body surface daily, improve-
ment in SCORAD and hypothalamic±
pituitary±adrenal axis suppression measured










1 0 29% 0´28 58´5
2 0 9% 0´46 153´6
3 564 36% 0´55 212´9
4 728 76% 0´39 b
5 835 82% 0´36 b
6 957 83% 0´09 18´4
7 1129 83% 0´03 6´3
8 2071 83% 0´33 79
aMean values of daily measurement under treatment; burine could not be obtained. The absolute
amount of applied corticosteroid (FP mg m22 daily) was related to the mean of daily
measurements of 06´00 h serum cortisol (Spearman's test, r  2 0´73, P , 0´05) but not to
the mean of daily measurements of urinary cortisol/creatinine ratio (Spearman's test,
r  2 0´38, P  0´5).
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safe, because susceptibility for HPA axis suppression is
highly variable. However, this treatment was highly
effective in severe and refractory AD. Furthermore,
these preliminary data suggest that a 5% dilution of the
corticosteroid seems to have comparable efficacy, but
lower systemic bioactivity, than 10% or 25% dilutions
under wet wrap, and that 1 week of treatment is
sufficient to achieve major improvement. Further study
in a larger number of children will be necessary to
establish the efficacy and the safety of weaker cortico-
steroid dilutions under wet-wrap dressings for long-
term treatment, as the practicality and benefits of such
long-term treatment are questionable.
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